PDS Biotechnology

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …

London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …

RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers   London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …

RNS Number : 5158O NetScientific PLC 09 February 2016   NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …

RNS Number : 4379M NetScientific PLC 20 January 2016 NetScientific plc   PDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes   London, UK – 20 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, …